Literature DB >> 29805526

[18F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis.

Lu Sun1, Yuanfei Dong2, Na Zhang1, Xing Lv1, Qiusong Chen2, Wei Wei1.   

Abstract

[18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) is useful for diagnosing cancers and inflammatory diseases. A polymyositis/dermatomyositis (PM/DM) lesion is an inflammatory heterogeneous disease of the striated muscle. In the present study, the maximum standardized uptake value (SUVmax) was compared between 22 cases with definite or probable PM/DM (PM/DM group) that underwent [18F]FDG-PET/CT examination and the same number of patients with no myopathy. The average proximal muscle FDG uptake value (SUVaverage) for each patient was represented by calculating the average of the SUVmax for these muscles bilaterally. The correlation between creatine kinase (CK), serum creatine kinase isoenzyme, myodynamia of the proximal limb girdle muscle and SUVmax of each muscle group were analyzed. The results indicated that the SUVmax was markedly different between the PM/DM group and the non-myopathy group. It was demonstrated that [18F]FDG-PET/CT has a diagnostic value for PM/DM. The serum CK levels and the SUVaverage were negatively correlated with myodynamia. [18F]FDG-PET/CT may be used for examination to assess the severity of myositis. Furthermore, it may provide detection sites for muscle biopsy in patients with myositis.

Entities:  

Keywords:  [18F]fluorodeoxyglucose positron emission tomography/computed tomography; aspartate aminotransferase; creatine kinase; creatine kinase isoenzyme; lactate dehydrogenase; polymyositis/dermatomyositis

Year:  2018        PMID: 29805526      PMCID: PMC5958694          DOI: 10.3892/etm.2018.6066

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  20 in total

Review 1.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 2.  Thymic carcinoma associated with paraneoplastic polymyositis.

Authors:  Yoshio Inoue; Lawrence D True; Renato G Martins
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

Review 3.  Unparalleled contribution of 18F-FDG PET to medicine over 3 decades.

Authors:  Sandip Basu; Abass Alavi
Journal:  J Nucl Med       Date:  2008-10       Impact factor: 10.057

4.  Morphologic imaging in muscular dystrophies and inflammatory myopathies.

Authors:  Adrian Degardin; David Morillon; Arnaud Lacour; Anne Cotten; Patrick Vermersch; Tanya Stojkovic
Journal:  Skeletal Radiol       Date:  2010-05-07       Impact factor: 2.199

Review 5.  Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Nat Clin Pract Rheumatol       Date:  2006-04

6.  Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis.

Authors:  Albert Selva-O'Callaghan; Josep M Grau; Cristina Gámez-Cenzano; Antonio Vidaller-Palacín; Xavier Martínez-Gómez; Ernesto Trallero-Araguás; Eduard Andía-Navarro; Miquel Vilardell-Tarrés
Journal:  Am J Med       Date:  2010-06       Impact factor: 4.965

7.  Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies.

Authors:  Takeshi Uenaka; Hisatomo Kowa; Yoshihisa Ohtsuka; Tsuneyoshi Seki; Kenji Sekiguchi; Fumio Kanda; Tatsushi Toda
Journal:  Eur Neurol       Date:  2017-10-19       Impact factor: 1.710

Review 8.  PET/CT imaging of inflammatory bowel disease.

Authors:  Scott B Perlman; Benjamin S Hall; Mark Reichelderfer
Journal:  Semin Nucl Med       Date:  2013-11       Impact factor: 4.446

9.  Role of 18F-FDG PET/CT in the diagnosis of inflammatory and infectious vascular disease.

Authors:  Beata Ewa Chrapko; Marek Chrapko; Anna Nocuń; Bogusław Stefaniak; Tomasz Zubilewicz; Andrzej Drop
Journal:  Nucl Med Rev Cent East Eur       Date:  2016

10.  Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation.

Authors:  Maki Tateyama; Kazuo Fujihara; Tatsuro Misu; Akira Arai; Tomohiro Kaneta; Masashi Aoki
Journal:  BMJ Open       Date:  2015-01-12       Impact factor: 2.692

View more
  5 in total

Review 1.  PET Scan: Nuclear Medicine Imaging in Myositis.

Authors:  Albert Selva-O'Callaghan; Albert Gil-Vila; Marc Simó-Perdigó; Ernesto Trallero-Araguás; Marcelo Alvarado-Cárdenas; Iago Pinal-Fernandez
Journal:  Curr Rheumatol Rep       Date:  2019-11-21       Impact factor: 4.592

2.  Value of 18F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis.

Authors:  Xiuming Li; Haibo Tan
Journal:  Heliyon       Date:  2020-04-03

Review 3.  The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis.

Authors:  Halil Yildiz; Philippe D'abadie; Olivier Gheysens
Journal:  Front Med (Lausanne)       Date:  2022-04-15

4.  PET-MRI in idiopathic inflammatory myositis: a comparative study of clinical and immunological markers with imaging findings.

Authors:  Manu Santhappan Girija; Ravindu Tiwari; Seena Vengalil; Saraswati Nashi; Veeramani Preethish-Kumar; Kiran Polavarapu; Karthik Kulanthaivelu; Arpana Arbind; Mainak Bardhan; Akshata Huddar; Gopikrishnan Unnikrishnan; Valasani Ravi Kiran; Tanushree Chawla; Bevinahalli Nandeesh; Chandana Nagaraj; Atchayaram Nalini
Journal:  Neurol Res Pract       Date:  2022-10-10

Review 5.  MRI and muscle imaging for idiopathic inflammatory myopathies.

Authors:  Samuel Malartre; Damien Bachasson; Guillaume Mercy; Elissone Sarkis; Céline Anquetil; Olivier Benveniste; Yves Allenbach
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.